PTCT - PTCセラピュ―ティクス (PTC Therapeutics Inc.)


   PTC Therapeutics''s Return On Capital Employed Overview  2022/11/02 14:19:10 Benzinga
According to Benzinga Pro data, during Q3, PTC Therapeutics (NASDAQ: PTCT ) posted sales of $217.13 million. Earnings were up 28.12%, but PTC Therapeutics still reported an overall loss of $109.31 million. PTC Therapeutics collected $165.53 million in revenue during Q2, but reported earnings showed a $152.09 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a … Full story available on
   What To Expect As PTC Therapeutics Inc. (NASDAQ: PTCT) Delivers An 8.89% Loss In 6 Months  2022/10/29 20:00:00 Marketing Sentinel
During the last session, PTC Therapeutics Inc. (NASDAQ:PTCT)’s traded shares were 1.89 million, with the beta value of the company hitting 0.56. At the end of the trading day, the stock’s price was $38.47, reflecting an intraday loss of -13.73% or -$6.12. The 52-week high for the PTCT share is $55.58, that puts it down … What To Expect As PTC Therapeutics Inc. (NASDAQ: PTCT) Delivers An 8.89% Loss In 6 Months Read More »
   PTC Therapeutics Grabs Up to $1 Billion, but There''s a Catch  2022/10/28 20:03:33 The Street
The drug developer''s financing deal with Blackstone has several strings attached.
   PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall  2022/10/28 15:08:17 Benzinga
PTC Therapeutics Inc (NASDAQ: PTCT ) entered into a strategic financing collaboration with Blackstone Inc (NYSE: BX ). As part of the collaboration, Blackstone Life Sciences and Blackstone Credit will provide PTC with an initial $500 million commitment, including $350 million in low-cost, low-dilution capital. "This strategic financing will support the … Full story available on
   PTC Therapeutics Inc. (PTCT) can beat the pack with these strategies  2022/10/28 11:40:00 US Post News
In Thursday’s session, PTC Therapeutics Inc. (NASDAQ:PTCT) marked $44.59 per share, down from $45.65 in the previous session. While PTC Therapeutics Inc. has underperformed by -2.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTCT rose by 25.78%, with highs and lows ranging from $55.58 to […]
   PTC Therapeutics GAAP EPS of -$1.78 misses by $0.27, revenue of $149M beats by $2.1M  2022/05/03 20:05:23 Seeking Alpha
   PTC Therapeutics Q1 2022 Earnings Preview  2022/05/02 21:45:00 Seeking Alpha
PTC Therapeutics (PTCT) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, after market close.The consensus EPS Estimate is -$1.66 and the consensus Revenue Estimate…
   PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results  2022/04/19 12:00:00 PR Newswire
SOUTH PLAINFIELD, N.J., April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company''s business and outlook on Tuesday, May…
   PTC Therapeutics expects EMA committee opinion on AADC deficiency gene therapy in May  2022/04/14 13:27:17 Seeking Alpha
Biopharmaceutical company PTC Therapeutics (PTCT) on Thursday said it has completed procedural meetings for its gene therapy treatment for ((AADC)) deficiency with the European Union…
   PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases  2022/04/11 11:13:37 Seeking Alpha
   PTC Therapeutics (NASDAQ:PTCT) Shares Gap Down to $40.85  2021/12/23 16:08:44 Transcript Daily
PTC Therapeutics, Inc. (NASDAQ:PTCT) gapped down before the market opened on Thursday . The stock had previously closed at $40.85, but opened at $39.58. PTC Therapeutics shares last traded at $41.26, with a volume of 80 shares. PTCT has been the subject of several research analyst reports. Credit Suisse Group reduced their target price on []
   PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected to Post Quarterly Sales of $134.21 Million  2021/12/21 21:34:44 Transcript Daily
Equities research analysts expect PTC Therapeutics, Inc. (NASDAQ:PTCT) to announce sales of $134.21 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for PTC Therapeutics earnings. The lowest sales estimate is $96.34 million and the highest is $162.70 million. PTC Therapeutics posted sales of $118.86 million in the same quarter []
   PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Fisher Asset Management LLC  2021/12/16 10:26:42 Transcript Daily
Fisher Asset Management LLC lifted its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 9.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 176,156 shares of the biopharmaceutical companys stock after purchasing an additional 15,671 shares during []
   PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Invesco Ltd.  2021/12/09 09:46:42 Dakota Financial News
Invesco Ltd. grew its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 38.6% in the second quarter, Holdings reports. The institutional investor owned 39,623 shares of the biopharmaceutical companys stock after buying an additional 11,041 shares during the quarter. Invesco Ltd.s holdings in PTC Therapeutics were worth $1,675,000 at the end of the most recent []
   Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight  2021/12/08 01:00:00 Benzinga
Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.